SEARCH

SEARCH BY CITATION

References

  • 1
    Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Ann Rev Pharmacol Toxicol 1984; 24: 17597.
  • 2
    Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88: 41115.
  • 3
    Radomski M, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987; 92: 1817.
  • 4
    Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 14829.
  • 5
    Moncada S, Radomski MW, Palmer RMJ. Endothelium-derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988; 37: 2495501.
  • 6
    Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 1987; 327: 5246.
  • 7
    Kelm M, Feelisch M, Spahr R, Piper H-M, Noack E, Schrader J. Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells. Biochem Biophys Res Commun 1988; 154: 23644.
  • 8
    Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 92659.
  • 9
    Khan MT, Furchgott RF. Additional evidence that endothelium-derived relaxing factor is nitric oxide. In: RandMJ, RaperC, eds. Pharmacology. New York : Elsevier, 1987;3414.
  • 10
    Amezcua JL, Dusting GJ, Palmer RMJ, Moncada S. Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodi-lator. Br J Pharmacol 1988; 95: 8304.
  • 11
    Kelm M, Schrader J. Nitric oxide release from the isolated guinea pig heart. Eur J Pharmacol 1988; 155: 31316.
  • 12
    Chen WZ, Palmer RMJ, Moncada S. The release of nitric oxide from the rabbit aorta. J Vase Med Biol 1989; 1: 26.
  • 13
    Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (Lond) 1988; 333: 6646.
  • 14
    Schmidt HHHW, Nau H, Wittfoht W, Gerlach J, Prescher K-E, Klein MM, Niroomand F, Bohme E. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 1988; 154: 21316.
  • 15
    Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988; 153: 12516.
  • 16
    Palmer RMJ, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989; 158: 34852.
  • 17
    Moncada S, Palmer RMJ. The L-arginine:nitric oxide pathway in the vessel wall. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-arginine: A Bioregulatory System. Amsterdam : Elsevier, 1990;1933.
  • 18
    Mayer B, Schmidt K, Humbert R, Bohme E. Biosynthesis of endothelium-derived relaxing factor: a cytosolic enzyme in porcine aortic endothelial cells Ca2+ dependency converts L-arginine into an activator of soluble guanylyl cyclase. Biochem Biophys Res Commun 1989; 164: 67885.
  • 19
    Mulsch A, Bassenge E, Busse R. Nitric oxide synthesis in endothelial cytosol: evidence for a calcium-dependent and a calcium-independent mechanism. Naunyn-Schmiedeberg's Arch Pharmacol 1989; 340: 76770.
  • 20
    Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96: 41824.
  • 21
    Sakuma I, Stuehr D, Gross SS, Nathan C, Levi R. Identification of arginine as a precursor of endothelium-derived relaxing factor (EDRF). Proc Natl Acad Sci USA 1988; 85: 86647.
  • 22
    Amezcua JL, Palmer RMJ, de Souza BM, Moncada S. Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol 1989; 97: 111924.
  • 23
    Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 33758.
  • 24
    Aisaka K, Gross SS, Griffith OW, Levi R. NG-Methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989; 160: 8816.
  • 25
    Whittle BJR, Lopez-Belmonte J, Rees DD. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol 1989; 98: 64652.
  • 26
    Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. Regional haemodynamic effects of inhibiting endothelial cell production of nitric oxide with NG-monomethyl-L-arginine in conscious rats. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-arginine: A Bioregulatory System. Amsterdam : Elsevier, 1990;818.
  • 27
    Tolins J, Palmer RMJ, Moncada S, Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol 1990;258:H65562.
  • 28
    Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 74652.
  • 29
    Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 48692.
  • 30
    Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. Persistent haemodynamic changes following prolonged infusions of NG-monomethyl-L-arginine (L-NMMA) in conscious rats. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-arginine: A Bioregulatory System, Amsterdam : Elsevier, 1990;48991.
  • 31
    Chu A, Lin C-C, Chambers DE, Kuehl WD, Palmer RMJ, Moncada S, Cobb FR. Effects of inhibition of nitric oxide formation on basal tone and endothelium-dependent responses of the coronary arteries in awake dogs. J Clin Invest 1991; 87: 19648.
  • 32
    Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;ii:9971000.
  • 33
    Vallance P, Collier J, Moncada S. Nitric oxide synthesised from L-arginine mediates endothelium-dependent dilatation in human veins. Cardiovasc Res 1989; 23: 10537.
  • 34
    Rees DD, Schulz R, Hodson HF, Palmer RMJ, Moncada S. Identification of some novel inhibitors of the vascular nitric oxide synthase in vivo and in vitro. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-arginine: A Bioregulatory System. Amsterdam : Elsevier, 1990;4857.
  • 35
    Moore PK, al Swayeh OA, Chong NWS, Evans R, Mirzazadeh S, Gibson A. L-NG-Nitroarginine (NOARG) inhibits endothelium-dependent vasodilatation in the rabbit aorta and perfused rat mesentery. Br J Pharmacol 1989; 98: 905P.
  • 36
    Ishii K, Chang B, Kerwin JF, Huang ZJ, Murad F. NGnitro-L-arginine: a potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol 1990; 176: 21923.
  • 37
    Mulsch A, Busse R. NG-nitro-L-arginine (N5-[imino(nitroami-no)methyl]-L-ornithine) impairs endothelium-dependent dilations by inhibiting cytosolic nitric oxide synthesis from L-arginine. Naunyn-Schmiedeberg's Arch Pharmacol 1990; 341: 1437.
  • 38
    Fukuto JM, Wood KS, Byrns RE, Ignarro LJ. NG-amino-L-arginine: a new potent antagonist of L-arginine-mediated endothelium-dependent relaxation. Biochem Biophys Res Commun 1990; 168: 45865.
  • 39
    Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. Regional haemodynamic changes during oral ingestion of NG-monomethyl-L-arginine or NG-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br J Pharmacol 1990; 101: 1012.
  • 40
    Pohl U, Busse R, Kuon E, Bassenge E. Pulsatile perfusion stimulates the release of endothelial autacoids. J Appl Cardiol 1986; 1: 21535.
  • 41
    Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250:H11459.
  • 42
    Moncada S, Palmer RMJ, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988; 12: 36572.
  • 43
    Moncada S, Rees DD, Schulz R, Palmer RMJ. Development and mechanism of a specific supersensitivity to nitrovasodilators following inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA, 1991; 88: 216670.
  • 44
    Cannon WB, Rosenblueth A. The supersensitivity of denervated structures. New York : Macmillan, 1949.
  • 45
    Seidel CL, La Rochelle J. Venous and arterial endothelia: different dilator abilities in dog vessels. Circ Res 1987; 60: 62630.
  • 46
    Laws GC. The effects of nitroglycerin on those who manufacture it. J Am Med Assoc 1898; 31: 7934.
  • 47
    Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218: 73949.
  • 48
    Kukovetz WR, Holzmann S. Mechanism of nitrate-induced vasodilatation and tolerance. Z Kardiol 1983; 72: 1419.
  • 49
    Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983; 88: 719.
  • 50
    Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986; 35: 352531.
  • 51
    Fleming WW, McPhillips JJ, Westfall DP. Postjunctional supersensitivity and subsensitivity of excitable tissues to drugs. Ergeb Physiol 1973; 68: 55119.
  • 52
    Bult H, Buyssens N, de Meyer GRY, Jordaens FH, Herman AG. Effects of chronic treatment with a source of exogenous nitric oxide on the release of endothelium-derived relaxing factor by aortae from normal and hypercholesterolaemic rabbits. In: S.Moncada, E.A.Higgs, eds. Nitric Oxide From L-arginine: A Bioregulatory System. Amsterdam : Elsevier, 1990:1016.
  • 53
    Winquist RJ, Bunting PB, Baskin EP, Wallace AA. Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive rats. J Hypertens 1984; 2: 5415.
  • 54
    de Mey JG, Gray SD. Endothelium-dependent reactivity in resistance vessels. Prog Appl Microcirc 1985; 8: 1817.
  • 55
    Luscher TF, Raij L, Vanhoutte PM. Effect of hypertension and its reversal on endothelium-dependent relaxations in the rat aorta. J Hypertens 1987;5:S1535.
  • 56
    Otsuka U, Dipiero A, Hirt E, Brennaman B, Lockette W. Vascular relaxation and cGMP in hypertension. Am J Physiol 1988;254:H1639.
  • 57
    Sunano S, Osugi S, Shimamura K. Blood pressure and impairment of endothelium-dependent relaxation in spontaneously hypertensive rats. Experientia 1989; 45: 7058.
  • 58
    Hagen GC, Webb RC. Coronary artery reactivity in deoxycorticosterone acetate hypertensive rats. Am J Physiol 1984;247:H40914.
  • 59
    Konishi M, Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension 1983; 5: 8816.
  • 60
    Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81: 17627.
  • 61
    Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 227.
  • 62
    Durante W, Sen AK, Sunahara FA. Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol 1988; 94: 4638.
  • 63
    Kappagoda T, Jayakody L, Rajotte R, Thomson ABR, Senaratne MPJ. Endothelium-dependent relaxation to acetylcholine in the aorta of streptozotocin induced diabetic-rat and the BB-diabetic rat. Clin Invest Med 1989; 12: 18793.
  • 64
    Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 1989; 97: 61418.
  • 65
    Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 4328.
  • 66
    Coene M-C, Herman AG, Jordaens F, van Hove C, Verbeuren TJ, Zonnekeyn L. Endothelium-dependent relaxations in isolated arteries of control and hypercholesterolemic rabbits. Br J Pharmacol 1985; 85: 267P.
  • 67
    Verbeuren TJ, Jordaens FH, Zonnekeyn IX, van Hove CE, Coene M-C, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 1986; 58: 55264.
  • 68
    Sreeharan N, Jayakody RL, Senaratne MPJ, Thomson ABR, Kappagoda CT. Endothelium-dependent relaxation and experimental atherosclerosis in the rabbit aorta. Can J Physiol Pharmacol 1986; 64: 14513.
  • 69
    Henry PD, Bossaller C, Yammamoto H. Impaired endothelium-dependent relaxation and cyclic guanosine 5′-monophos-phate formation in atherosclerotic human coronary artery and rabbit aorta. Thromb Res Suppl 1987;VII:6.
  • 70
    Guerra R Jr, Brotherton AFA, Goodwin PJ, Clark CR, Armstrong ML, Harrison DG. Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: implications for altered autocrine and paracrine functions of EDRF. Blood Vessels 1989; 26: 30014.
  • 71
    Forstermann U. Properties and mechanisms of production and action of endothelium-derived relaxing factor. J Cardiovasc Pharmacol 1986;8:S4551.
  • 72
    Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Araki H, Nakamura M, Ishii Y, Tanaka K. Coronary artery spasm induced in atherosclerotic miniature swine. Science 1983; 221: 5601.
  • 73
    Drexler H, Zeiher AM, Wollshlager H, Meinertz T, Just H, Bonzel T. Flow-dependent coronary artery dilatation in humans. Circulation 1989; 80: 46674.
  • 74
    Chester AH, O'Neil GS, Moncada S, Tadjkarimi S, Yacoub MH. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990; 336: 897900.
  • 75
    Jacobs M, Plane F, Bruckdorfer R. Inhibition of endothelium-derived nitric oxide and atherosclerosis. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-Arginine: A Biotegulatory System. Amsterdam : Elsevier, 1990;10714.
  • 76
    Dinh-Xuan AT, Higenbottam TW, Pepke-Zaba J, Clelland CA, Wallwork J. Reduced endothelium-dependent relaxation of cystic fibrosis pulmonary arteries. Eur J Pharmacol 1989; 163: 4013.
  • 77
    Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Wallwork J. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol 1990; 90: 910.
  • 78
    Dinh-Xuan AT, Higenbottam TW, Pepke-Zaba J, Cremona G, Clelland CA, Wallwork J. Physiological and histological correlates of pulmonary endothelium-dependent relaxation in human chronic obstructive lung disease. Thorax 1990; 45: 810.
  • 79
    Fisher CM, Kistler JP, Davis JM. The correlation of cerebral vasospasm and the amount of subarachnoid blood detected by computerized cranial tomography after aneurysm rupture. In: WilkinsRH, ed. Cerebral Artery Spasm. London, Baltimore : Williams and Wilkins, 1981;397408.
  • 80
    Kanamaru K, Waga S, Kojima T, Fujimoto K, Niwa S. Endothelium-dependent relaxation of canine basilar arteries. II. Inhibition by hemoglobin and cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage. Stroke 1987; 18: 93843.
  • 81
    Radomski MW, Palmer RMJ, Moncada S. An L-arginine:nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Sci USA 1990; 87: 51937.
  • 82
    Houston DS, Shepherd JT, Vanhoutte PM. Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets. Am J Physiol 1985;248:H38995.
  • 83
    Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 63946.
  • 84
    Sinzinger H, Fitscha P, O'Grady J, Rauscha F, Rogatti W, Vane JR. Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease. Lancet 1990; 335: 6278.
  • 85
    Miki N, Kawabe Y, Kuriyama K. Activation of cerebral guanylate cyclase by nitric oxide. Biochem Biophys Res Commun 1977; 75: 8516.
  • 86
    Deguchi T. Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. J Biol Chem 1977; 252: 761719.
  • 87
    Yoshikawa K, Kuriyama K. Characterization of cerebellar guanylate cyclase using N-methyl-N-nitro-N-nitrosoguani-dine. Presence of two different types of guanylate cyclase in soluble and particulate fraction. Biochim Biophys Acta 1980; 628: 37787.
  • 88
    Deguchi T, Yoshioka M. L-arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells. J Biol Chem 1982; 257: 1014752.
  • 89
    Knowles RG, Palacios M, Palmer RMJ, Moncada S. Formation of nitric oxide from L-arginine in the central nervous system. A transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci USA 1989; 86: 515962.
  • 90
    Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988; 336: 3858.
  • 91
    Garthwaite J, Garthwaite G, Palmer RMJ, Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989; 172: 41316.
  • 92
    Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 1989; 86: 90303.
  • 93
    Wood PL, Emmett MR, Rao TS, Cler J, Mick S, Iyengar S. Inhibition of nitric oxide synthase blocks N-methyl-D-aspartate-, quisqualate-, kainate-, harmaline- and pentylenetetra-zole-dependent increases in cerebellar cyclic GMP in vivo. J Neurochem 1990; 55: 3468.
  • 94
    Garthwaite J, Southam E, Anderton M. A kainate receptor linked to nitric oxide synthesis from arginine. J Neurochem 1989; 53: 19524.
  • 95
    Olson DR, Kon C, Breckenridge BM. Calcium ion effects on guanylate cyclase of brain. Life Sci 1976; 18: 93540.
  • 96
    Knowles RG, Palacios M, Palmer RMJ, Moncada S. Kinetic characteristics of nitric oxide synthase from rat brain. Biochem J 1990; 269: 20710.
  • 97
    Schmidt HHHW, Wilke P, Evers B, Bohme E. Enzymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol. Biochem Biophys Res Commun 1989; 165: 28491.
  • 98
    Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87: 6825.
  • 99
    Shibuki K, Okada D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature 1991; 349: 3268.
  • 100
    Drummond GI. Cyclic GMP. In: Cyclic Nucleotides in the Nervous System. New York : Raven Press, 1984;40125.
  • 101
    Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci 1987; 10: 299302.
  • 102
    Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 62334.
  • 103
    Garthwaite J. NMDA receptors, neuronal development and neuronal degeneration. In WatkinsJC, CollingridgeGL, eds. The NMDA Receptor. Oxford University Press, 1989: 187205.
  • 104
    Ross CA, Bredt D, Snyder SH. Messenger molecules in the cerebellum. Trends Neurosci 1990; 13: 21622.
  • 105
    Lolley RN, Farber DB, Rayborn ME, Hollyfield JG. Cyclic GMP accumulation causes degeneration of photoreceptor cells: simulation of an inherited disease. Science 1977; 196: 6646.
  • 106
    Ferrendelli JA, Chang MM, Kinscherf DA. Elevation of cyclic GMP levels in central nervous system by excitatory and inhibitory amino acids. J Neurochem 1974; 22: 53540.
  • 107
    Freedman R, Taylor D, Seiger A, Olson L, Hoffer B. Seizures and related epileptiform activity in hippocampus transplanted to the anterior chamber in the eye. II. Modulation by cholinergic and adrenergic input. Ann Neurol 1979; 6: 28193.
  • 108
    Meldrum B. Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc Brain Metab Rev 1990; 2: 2757.
  • 109
    Gillespie JS, Liu X, Martin W. The neurotransmitter of the non-adrenergic non-cholinergic inhibitory nerves to smooth muscle of the genital system. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-arginine: A Bioregulatory System. Amsterdam , Elsevier; 1990:14764.
  • 110
    Gustafsson LE, Wiklund NP, Wiklund CU, Cederqvist B, Persson MG, Moncada S. Modulation of autonomic neuroeffector transmission by nitric oxide-like activity in guinea-pig smooth muscle. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-Arginine: A Bioregulatory System. Amsterdam , Elsevier; 1990:17781.
  • 111
    Palacios M, Knowles RG, Palmer RMJ, Moncada S. Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun 1989; 165: 8029.
  • 112
    Derome G, Tseng R, Mercier P, Lemaire I, Lemaire S. Possible muscarinic regulation of catecholamine secretion mediated by cyclic GMP in isolated bovine adrenal chromaffin cells. Biochem Pharmacol 1981; 30: 85560.
  • 113
    Dohi T, Morita K, Tsujimoto A. Effect of sodium azide on catecholamine release from isolated adrenal gland and on guanylate cyclase. Eur J Pharmacol 1983; 94: 3315.
  • 114
    O'Sullivan AJ, Burgoyne RD. Cyclic GMP regulates nicotine-induced secretion from cultured bovine adrenal chromaffin cells. Effects of 8-bromo-cyclic GMP, atrial natriuretic peptide, and nitroprusside (nitric oxide). J Neurochem 1990; 54: 18058.
  • 115
    Perchellet JP, Shanker G, Sharma RK. Regulatory role of guanosine 3′,5′-monophosphate in adrenocorticotropin hormone-induced steroidogenesis. Science 1978; 199: 3112.
  • 116
    Ishii K, Gorsky LD, Forstermann U, Murad F. Endothelium-derived relaxing factor (EDRF): the endogenous activator of soluble guanylate cyclase in various types of cells. J Appl Cardiol 1989; 4: 50512.
  • 117
    Gorsky LD, Forstermann Y, Ishii K, Murad F. Production of an EDRF-like activity in the cytosol of N1E-115 neuroblastoma cells. FASEB J 1990; 4: 14941500.
  • 118
    Schroder H, Schror K. Cyclic GMP stimulation by vasopressin in LLC-PK1 kidney epithelial cells is L-arginine-dependent. Naunyn Schmiedeberg's Arch Pharmacol 1989; 340: 4757.
  • 119
    Salvemini D, Masini E, Anggard E, Mannaioni PF, Vane JR. Synthesis of a nitric oxide-like factor from L-arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation. Biochem Biophys Res Commun 1990; 169: 596601.
  • 120
    Hegesh E, Shiloah J. Blood nitrates and infantile methemoglobinemia. Clin Chim Acta 1982; 125: 10715.
  • 121
    Wagner DA, Young VR, Tannenbaum SR. Mammalian nitrate biosynthesis: incorporation of 15NH3 into nitrate is enhanced by endotoxin treatment. Proc Natl Acad Sci USA 1983; 80: 451821.
  • 122
    Wagner DA, Young VR, Tannenbaum SR, Schultz DS, Deen WM. Mammalian nitrate biochemistry: metabolism and endogenous synthesis. In: O'NeillIK, vonBorstelRC, LongJE, MillerCT, MartschH. eds. N-nitroso compounds: occurrence, biological effects and relevance to human cancer. IARC Scientific Publication 1984; 57: 24753.
  • 123
    Iyengar R, Stuehr DJ, Marietta MA. Macrophage synthesis of nitrite, nitrate and N-nitrosamines: precursors and role of the respiratory burst. Proc Natl Acad Sci USA 1987; 84: 636973.
  • 124
    Hibbs JB Jr, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138: 55065.
  • 125
    Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J Immunol 1988; 141: 240712.
  • 126
    Marietta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 1988; 27: 870611.
  • 127
    Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157: 8794.
  • 128
    Stuehr D, Gross S, Sakuma I, Levi R, Nathan C. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med 1989; 169: 101120.
  • 129
    Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 154355.
  • 130
    Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 1985; 82: 773842.
  • 131
    Stuehr DJ, Marietta MA. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines or interferon-γy. J Immunol 1987; 139: 51825.
  • 132
    Stuehr DJ, Marletta MA. Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res 1987; 47: 55904.
  • 133
    McCall TB, Feelisch M, Palmer RMJ, Moncada S. Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells. Br J Pharmacol 1991; 102: 2348.
  • 134
    Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem 1989; 264: 196548.
  • 135
    Kwon NS, Nathan CF, Stuehr DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989; 264: 20496501.
  • 136
    Stuehr DJ, Kwon NS, Nathan CF. FAD and GSH participate in macrophage synthesis of nitric oxide. Biochem Biophys Res Commun 1990; 168: 55865.
  • 137
    Hibbs JB Jr, Taintor RR, Vavrin Z, Granger DL, Drapier J-C, Amber IJ, Lancaster JR Jr. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-Arginine: A Bioregulatory System, Amsterdam : Elsevier, 1990:189223.
  • 138
    Granger DL, Perfect JR, Durack DT. Macrophage-mediated fungistasis in vitro: requirements for intracellular cytotoxicity. J Immunol 1986; 136: 67280.
  • 139
    Granger DL, Perfect JR, Durack DT. Macrophage-mediated fungistasis: requirements for a macromolecular component in serum. J Immunol 1986; 137: 693701.
  • 140
    Adams LB, Hibbs JB Jr, Taintor RR, Krahenbuhl JL. Micro-biostatic effect of murine macrophages for Toxoplasma gondii: role of synthesis of inorganic nitrogen oxides from L-arginine. J Immunol 1990; 144: 27259.
  • 141
    Green SG, Meltzer MS, Hibbs JB Jr, Nacy CA. Activated macrophages destroy intracellular Leishmania major amasti-gotes by an L-arginine dependent killing mechanism. J Immunol 1990; 144: 27883.
  • 142
    Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990; 144: 47947.
  • 143
    Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leuk Biol 1991; 49: 3807.
  • 144
    Rimele TJ, Sturm RJ, Adams LM, Henry DE, Heaslip RJ, Weichman BM, Grimes D. Interaction of neutrophils with vascular smooth muscle: identification of a neutrophil-derived relaxing factor. J Pharmacol Exp Ther 1988; 245: 10211.
  • 145
    Lee DKH, Faunce D, Henry D, Sturm R, Rimele T. Rat polymorphonuclear leukocytes (PMN) increase cGMP levels in rat aorta. FASEB J 1988;2:A518.
  • 146
    Cynk E, Kondo K, Salvemini D, Sneddon JM, Vane JR. Human monocytes and neutrophils inhibit platelet aggregation by releasing an EDRF-like factor. J Physiol 1988; 407: 23P.
  • 147
    Salvemini D, de Nucci G, Gryglewski RJ, Vane JR. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci USA 1989; 86: 632832.
  • 148
    McCall TB, Boughton-Smith NK, Palmer RMJ, Whittle BJR, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J 1989; 261: 2936.
  • 149
    Schmidt HHHW, Seifert R, Bohme E. Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by chemotactic peptide, platelet activating factor and leuko-triene B4. FEBS Letters 1989; 244: 35760.
  • 150
    Wright DC, Mulsch A, Busse R, Osswald H. Generation of nitric oxide by human neutrophils. Biochem Biophys Res Commun 1989; 160: 81319.
  • 151
    Billiar TR, Curran RD, Stuehr DJ, West MA, Bentz BG, Simmons RL. An L-arginine dependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro. J Exp Med 1989; 169: 146772.
  • 152
    Curran RD, Billiar TR, Stuehr DJ, Hofmann K, Simmons RL. Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products from Kupffer cells. J Exp Med 1989; 170: 176974.
  • 153
    Knowles RG, Merrett M, Salter M, Moncada S. Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. Biochem J 1990; 270: 8336.
  • 154
    Amber IJ, Hibbs JB Jr, Taintor RR, Vavrin Z. The L-arginine dependent effector mechanism is induced in murine adenocarcinoma cells by culture supernatant from cytotoxic activated macrophages. J Leuk Biol 1988; 43: 18792.
  • 155
    Lepoivre M, Boudbid H, Petit J-F. Antiproliferative activity of γy-interferon combined with lipopolysaccharide on murine adenocarcinoma: dependence on an L-arginine metabolism with production of nitrite and citrulline. Cancer Res 1989; 49: 19706.
  • 156
    Lepoivre M, Boudbid H, Petit J-F. Antitumour cytostatic effect of EMT6 cells treated with interferon-γy and lipopolysaccharide. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-arginine: A Bioregulatory System. Amsterdam : Elsevier, 1990:41522.
  • 157
    Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med 1990; 172: 1599607.
  • 158
    Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87: 100437.
  • 159
    Rees DD, Cellek S, Palmer RMJ, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone. An insight into endotoxin shock. Biochem Biophys Res Commun 1990; 173: 5417.
  • 160
    Knowles RG, Salter M, Brooks SL, Moncada S. Antiinflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun 1990; 172: 10428.
  • 161
    Parratt JR. Myocardial and circulatory effects of E. Coli endotoxin; modification of responses to catecholamines. Br J Pharmacol 1973; 47: 1225.
  • 162
    Wakabayashi I, Hatake K, Kakashita E, Nagai K. Diminution of contractile response of the aorta from endotoxin-injected rats. Eur J Pharmacol 1987; 141: 11722.
  • 163
    McKenna TM. Prolonged exposure of rat aorta to low levels of endotoxin in vitro results in impaired contractility: association with vascular cytokine release. J Clin Invest 1990; 86: 1608.
  • 164
    Fleming I, Gray GA, Julou-Schaeffer G, Parratt JR, Stoclet J-C. Incubation with endotoxin activates the L-arginine pathway in vascular tissue. Biochem Biophys Res Commun 1990; 171: 5628.
  • 165
    Billiar TR, Curran RD, Stuehr DJ, Stadler J, Simmons RL, Murray SA. Inducible cytosolic enzyme activity for the production of nitrogen oxides from L-arginine in hepatocytes. Biochem Biophys Res Commun 1990; 168: 103440.
  • 166
    Billiar TR, Curran RD, Stuehr DJ, Hofmann K, Simmons RL. Inhibition of L-arginine metabolism by NG-monomethyl-L-arginine in vivo promotes hepatic damage in response to lipopolysaccharide. In: MoncadaS, HiggsEA, eds. Nitric Oxide From L-Arginine: A Bioregulatory System. Amsterdam ; Elsevier, 1990:27580.
  • 167
    Hutcheson IR, Whittle BJR, Boughton-Smith NK. Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br J Pharmacol 1990; 101: 81520.
  • 168
    Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87: 362932.
  • 169
    Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopoly-saccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 5915.
  • 170
    Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 32: 35867.
  • 171
    Schrier RW, Caramelo C. Hemodynamic and hormonal alterations in hepatic cirrhosis. In: EpsteinM, ed. The Kidney In Liver Disease. Baltimore : Williams & Wilkins, 1988:26585.
  • 172
    Bosch J, Gines P, Arroyo V, Navasa M, Rodes J. Hepatic and systemic hemodynamics and the neurohumoral systems in cirrhosis. In: EpsteinM, ed. The Kidney In Liver Disease. Baltimore : Williams & Wilkins, 1988:286305.
  • 173
    Pizcueta P, Pique JM, Bosch J, Whittle BJR, Moncada S. Effects of endogenous nitric oxide inhibition on the hemodynamic changes of portal hypertensive rats. Gastroenterol 1991;100:A785.
  • 174
    Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral blood in patients with cirrhosis. Hepatol 1988; 8: 2326.
  • 175
    Yomota M, Kambayashi J, Tanaka T, Tsujinaka T, Sakon M, Mori T. A simple turbidometric time assay of the endotoxin in plasma. J Biochem Biophys Meth 1989; 18: 97104.
  • 176
    Miyase S, Fujiyama S, Chikazawa H, Sato T. Atrial natriuretic peptide in liver cirrhosis with mild ascites. Gastroenterol Jpn 1990; 25: 35662.
  • 177
    Vallance P, Moncada S. Hypothesis: induction of nitric oxide synthase in the vasculature underlies the hyperdynamic circulation of cirrhosis. Lancet 1991; 337: 7768.
  • 178
    Hinshaw LB, Archer LT, Beller-Todd BK, Coalson JJ, Flour-noy DJ, Passey R, Benjamin B, White GL. Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res 1980; 28: 15170.
  • 179
    Greisman SE. Experimental gram-negative bacterial sepsis: optimal methyl-prednisolone requirements for prevention of mortality not preventable by antibiotics alone. Proc Soc Exp Biol Med 1982; 170: 43642.
  • 180
    Nicholson DP. Glucocorticoids in the treatment of shock and the adult respiratory distress syndrome. Clin Chest Med 1982; 3: 12132.
  • 181
    Hoffman SL, Punjabi NH, Kumala S, Moechtar MA, Pulungsih SP, Rival AR, Rockhill RC, Woodward TE, Loedin AA. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984; 310: 828.
  • 182
    Haynes RC Jr, Murad F Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogues: inhibitors of adrenocortical steroid biosynthesis. In: GilmanA, GoodmanLS, RailTW, MuradF, eds. The Pharmacological Basis of Therapeutics, 7th edn. New York ; Macmillan, 1985: 145989.
  • 183
    Di Rosa M, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 1990; 172: 124652.
  • 184
    Schaffner A, Schaffner T. Glucocorticoid-induced impairment of macrophage antimicrobial activity: mechanisms and dependence on the state of activation. Rev Infect Dis 1987;9 (Suppl.5): S6209.
  • 185
    Schulz RM, Nanda SKW, Altom MG. Effects of various inhibitors of arachidonic acid oxygenation on macrophage superoxide release and tumoricidal activity. J Immunol 1985; 135: 20404.
  • 186
    Hogan MM, Vogel SN. Inhibition of macrophage tumoricidal activity by glucocorticoids. J Immunol 1988; 140: 5139.
  • 187
    Conn DL. Update on systemic necrotizing vasculitis. Mayo Clin Proc 1989; 64: 53543.
  • 188
    Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 170915.
  • 189
    Fehleisen F. Uber di Zuchtung der Erysipelkokken auf kunst-lichen Nahrboden und ihr Ubertragbarkeit auf den Menschen. Dt. med. Wschr. 1882; 8: 553.
  • 190
    Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci 1893; 105: 487511.